Sanfang Tu

5PUBLICATIONS
9CO-AUTHORS
Cancer therapy (excl. chemotherapy and radiation therapy)Gene and molecular therapyHaematological tumours
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (5)

|May 07, 2024
Dendritic cell vaccines extend CAR T-cell persistence and improve the efficacy of CD19 CAR T-cell therapy in refractory or relapsed adult B-ALL patients.

Sanfang Tu, Lijuan Zhou, Rui Huang

|Nov 13, 2023
Risk-directed therapy based on genetics and MRD improves the outcomes of AML1-ETO-positive AML patients, a multi-center prospective cohort study.

Dan Xu, Ying Yang, Zhao Yin

|Jan 21, 2022
The role of allogeneic haematopoietic cell transplantation as consolidation after anti-CD19 CAR-T cell therapy in adults with relapsed/refractory acute lymphoblastic leukaemia: a prospective cohort study.

Shi Han, Lijuan Zhou, Youyou Chen

|Jan 08, 2021
Preclinical and clinical advances in dual-target chimeric antigen receptor therapy for hematological malignancies.

Zhenling Guo, Sanfang Tu, Siyao Yu

|Sep 07, 2019
Shortening the ex vivo culture of CD19-specific CAR T-cells retains potent efficacy against acute lymphoblastic leukemia without CAR T-cell-related encephalopathy syndrome or severe cytokine release syndrome.

Sanfang Tu, Rui Huang, Zhenling Guo

Pageof 1

Frequent Collaborators

1 joint publications

Yanjie He

1 joint publications

Shi Han

1 joint publications

Yuhua Li

1 joint publications

Dan Xu